On 2 March Opexa announced it has embarked on a restructuring initiative to prioritize its spending towards completing the ongoing 190-patient AbiliT Phase II study of lead candidate Tcelna in secondary progressive multiple sclerosis (SPMS). The company has reduced its overall headcount by about 30%, but this does not affect the Abili-T study timelines, for which data are expected in early Q416. The restructuring lengthens the company’s financial runway into Q117 (vs prior guidance of Q
01 Apr 2016
Restructuring sharpens focus on Tcelna data
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Restructuring sharpens focus on Tcelna data
- Published:
01 Apr 2016 -
Author:
Pooya Hemami -
Pages:
6
On 2 March Opexa announced it has embarked on a restructuring initiative to prioritize its spending towards completing the ongoing 190-patient AbiliT Phase II study of lead candidate Tcelna in secondary progressive multiple sclerosis (SPMS). The company has reduced its overall headcount by about 30%, but this does not affect the Abili-T study timelines, for which data are expected in early Q416. The restructuring lengthens the company’s financial runway into Q117 (vs prior guidance of Q